Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 8/20 | 0.62 |
| ▸ | JAK2 | O60674 | 6/20 | 0.62 |
| ▸ | JAK1 | P23458 | 5/20 | 0.62 |
| ▸ | JAK3 | P52333 | 5/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 6/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409547 | 1.00 | TYK2 (0.62) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18398513 | 1.00 | TYK2 (0.62) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18409549 | 1.00 | TYK2 (0.62) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18409175 | 0.94 | TYK2 (0.64) | TYK2JAK2JAK1JAK3IDO1 | |
| SCHEMBL18409298 | 0.92 | TYK2 (0.56) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18408926 | 0.91 | TYK2 (0.50) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18409163 | 0.90 | TYK2 (0.75) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409456 | 0.90 | TYK2 (0.49) | TYK2JAK2JAK1JAK3LRRK2 | |
| SCHEMBL18409441 | 0.88 | JAK2 (0.48) | TYK2JAK2JAK1JAK3MAP4K1 | |
| SCHEMBL18409401 | 0.88 | TYK2 (0.61) | TYK2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |